Piramal Pharma Share Price
Sector: Biotechnology & Drugs
214.95 -1.05 (-0.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
213.45
Today’s High
219.90
52 Week Low
135.85
52 Week High
307.85
214.81 -1.44 (-0.67%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
213.31
Today’s High
219.95
52 Week Low
136.10
52 Week High
307.90
Key Metrics
- Market Cap (In Cr) 28431.14
- Beta -
- Div. Yield (%) 0.05
- P/B 3.62
- TTM P/E 915.83
- Peg Ratio -10.77
- Sector P/E 26.62
- Open Price 215.05
- Prev Close 216
Piramal Pharma Analysis
Price Analysis
-
1 Week-1.89%
-
3 Months-7.21%
-
6 Month-11.53%
-
YTD-18.78%
-
1 Year52.34%
Risk Meter
- 50% Low risk
- 50% Moderate risk
- 50% Balanced Risk
- 50% High risk
- 50% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 5
- 5
- 4
- 3
- Buy
- 4
- 3
- 2
- 3
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 9
- 8
- 6
- 6
Piramal Pharma News
The Piramal success formula: Consensus for father, data for daughter
7 min read . 31 Mar 2025Holi 2025: Two stock picks by Bajaj Broking for more than 15% upside
1 min read . 14 Mar 2025Stocks to watch: Tata Motors, Paytm, M&M among shares in focus today
3 min read . 03 Mar 2025Piramal Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 8171.16
- Selling/ General/ Admin Expenses Total
- 2634.67
- Depreciation/ Amortization
- 740.57
- Other Operating Expenses Total
- -50.92
- Total Operating Expense
- 6683.37
- Operating Income
- 1487.79
- Net Income Before Taxes
- 179.29
- Net Income
- 17.82
- Diluted Normalized EPS
- 0.46
- Period
- 2024
- Total Assets
- 15311.81
- Total Liabilities
- 7400.44
- Total Equity
- 7911.37
- Tangible Book Valueper Share Common Eq
- 27.38
- Period
- 2024
- Cashfrom Operating Activities
- 1004.54
- Cashfrom Investing Activities
- -434.01
- Cashfrom Financing Activities
- -422.36
- Net Changein Cash
- 165.96
- Period
- 2023
- Total Revenue
- 7081.55
- Selling/ General/ Admin Expenses Total
- 2416.27
- Depreciation/ Amortization
- 676.69
- Other Operating Expenses Total
- -159.77
- Total Operating Expense
- 5937.62
- Operating Income
- 1143.93
- Net Income Before Taxes
- -120.15
- Net Income
- -186.46
- Diluted Normalized EPS
- -1.49
- Period
- 2023
- Total Assets
- 14522.56
- Total Liabilities
- 7749.06
- Total Equity
- 6773.5
- Tangible Book Valueper Share Common Eq
- 19.12
- Period
- 2023
- Cashfrom Operating Activities
- 483.89
- Cashfrom Investing Activities
- -1338.78
- Cashfrom Financing Activities
- 817.79
- Net Changein Cash
- -31.95
- Period
- 2022
- Total Revenue
- 6559.1
- Selling/ General/ Admin Expenses Total
- 1997.5
- Depreciation/ Amortization
- 586.18
- Other Operating Expenses Total
- -77
- Total Operating Expense
- 5264.9
- Operating Income
- 1294.2
- Net Income Before Taxes
- 484.98
- Net Income
- 375.96
- Diluted Normalized EPS
- 3.21
- Period
- 2022
- Total Assets
- 12797.04
- Total Liabilities
- 6100.44
- Total Equity
- 6696.6
- Tangible Book Valueper Share Common Eq
- 19.44
- Period
- 2022
- Cashfrom Operating Activities
- 843.16
- Cashfrom Investing Activities
- -1812.1
- Cashfrom Financing Activities
- 794.19
- Net Changein Cash
- -176.79
- Period
- 2021
- Total Revenue
- 2938.81
- Selling/ General/ Admin Expenses Total
- 456.69
- Depreciation/ Amortization
- 143.64
- Other Operating Expenses Total
- -52.4
- Total Operating Expense
- 1844.83
- Operating Income
- 1093.98
- Net Income Before Taxes
- 686.78
- Net Income
- 571.5
- Diluted Normalized EPS
- 4.7
- Period
- 2021
- Total Assets
- 5756.67
- Total Liabilities
- 1656.05
- Total Equity
- 4100.62
- Tangible Book Valueper Share Common Eq
- 30.78
- Period
- 2021
- Cashfrom Operating Activities
- 34.72
- Cashfrom Investing Activities
- -4382.89
- Cashfrom Financing Activities
- 4494.16
- Net Changein Cash
- 145.99
- Period
- 2024-12-31
- Total Revenue
- 2204.22
- Selling/ General/ Admin Expenses Total
- 556.24
- Depreciation/ Amortization
- 196.81
- Other Operating Expenses Total
- 504.41
- Total Operating Expense
- 2063.29
- Operating Income
- 140.93
- Net Income Before Taxes
- 66.8
- Net Income
- 3.68
- Diluted Normalized EPS
- 0.03
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 2241.75
- Selling/ General/ Admin Expenses Total
- 559.53
- Depreciation/ Amortization
- 192.22
- Other Operating Expenses Total
- 544.14
- Total Operating Expense
- 2092.36
- Operating Income
- 149.39
- Net Income Before Taxes
- 120.12
- Net Income
- 22.59
- Diluted Normalized EPS
- 0.17
- Period
- 2024-09-30
- Total Assets
- 15241.74
- Total Liabilities
- 7334.57
- Total Equity
- 7907.17
- Tangible Book Valueper Share Common Eq
- 28.26
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 184.71
- Cashfrom Investing Activities
- -74.42
- Cashfrom Financing Activities
- -262.51
- Net Changein Cash
- -157.52
- Period
- 2024-06-30
- Total Revenue
- 1951.14
- Selling/ General/ Admin Expenses Total
- 579.69
- Depreciation/ Amortization
- 184.55
- Other Operating Expenses Total
- 492.59
- Total Operating Expense
- 1931.2
- Operating Income
- 19.94
- Net Income Before Taxes
- -45.08
- Net Income
- -88.64
- Diluted Normalized EPS
- -0.67
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2552.36
- Selling/ General/ Admin Expenses Total
- 526.05
- Depreciation/ Amortization
- 196.13
- Other Operating Expenses Total
- -26.38
- Total Operating Expense
- 1740.71
- Operating Income
- 811.65
- Net Income Before Taxes
- 227.48
- Net Income
- 101.27
- Diluted Normalized EPS
- 0.86
- Period
- 2024-03-31
- Total Assets
- 15311.81
- Total Liabilities
- 7400.44
- Total Equity
- 7911.37
- Tangible Book Valueper Share Common Eq
- 27.38
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1004.54
- Cashfrom Investing Activities
- -434.01
- Cashfrom Financing Activities
- -422.36
- Net Changein Cash
- 165.96
- Period
- 2023-12-31
- Total Revenue
- 1958.57
- Selling/ General/ Admin Expenses Total
- 523.78
- Depreciation/ Amortization
- 186.32
- Other Operating Expenses Total
- -61.51
- Total Operating Expense
- 1356.01
- Operating Income
- 602.56
- Net Income Before Taxes
- 19.36
- Net Income
- 10.11
- Diluted Normalized EPS
- 0.21
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1911.38
- Selling/ General/ Admin Expenses Total
- 516.03
- Depreciation/ Amortization
- 184.51
- Other Operating Expenses Total
- -49.19
- Total Operating Expense
- 1289.08
- Operating Income
- 622.3
- Net Income Before Taxes
- 39.56
- Net Income
- 5.02
- Diluted Normalized EPS
- 0.04
- Period
- 2023-09-30
- Total Assets
- 14775.69
- Total Liabilities
- 7017.83
- Total Equity
- 7757.86
- Tangible Book Valueper Share Common Eq
- 25.88
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 508.25
- Cashfrom Investing Activities
- -107.18
- Cashfrom Financing Activities
- -386.52
- Net Changein Cash
- 19.99
- Period
- 2023-06-30
- Total Revenue
- 1748.85
- Selling/ General/ Admin Expenses Total
- 495.54
- Depreciation/ Amortization
- 173.61
- Other Operating Expenses Total
- -38.31
- Total Operating Expense
- 1257.57
- Operating Income
- 491.28
- Net Income Before Taxes
- -107.11
- Net Income
- -98.58
- Diluted Normalized EPS
- -0.83
- Period
- 2023-06-30
- Period
- 2023-06-30
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Piramal Pharma Technical
Moving Average
SMA
- 5 Day220.97
- 10 Day219.73
- 20 Day221.52
- 50 Day212.05
- 100 Day229.83
- 300 Day219.53
Piramal Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ajanta Pharma
- 2781.9
- 104.7
- 3.91
- 3485.75
- 2022.05
- 34749.3
- Suven Pharmaceuticals
- 1154
- 10.75
- 0.94
- 1359
- 597
- 29495.48
- Piramal Pharma
- 214.95
- -1.05
- -0.49
- 307.85
- 135.85
- 28431.14
- Syngene International
- 616.85
- -12.8
- -2.03
- 960
- 608
- 24830.49
- J B Chemicals And Pharmaceutical
- 1605.9
- 29.85
- 1.89
- 2029
- 1303
- 24962.19
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ajanta Pharma
- 41.19
- 9.45
- 21.37
- 19.31
- Suven Pharmaceuticals
- 96.12
- 14.19
- 27.91
- 33.21
- Piramal Pharma
- 470.1
- 3.62
- -
- -
- Syngene International
- 53.66
- 5.35
- 13.02
- 15.03
- J B Chemicals And Pharmaceutical
- 45.15
- 8.35
- 20.54
- 16.06
Piramal Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-Jan-25
- Quarterly Results
- 23-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 24-May-23
- Audited Results
- 08-Feb-23
- Quarterly Results & Rights issue
- 08-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 23-Mar-25
- 19-Feb-25
- POM
- 26-Jul-24
- 11-Jun-24
- AGM
- 31-Jul-23
- 16-Jun-23
- AGM
- 22-Mar-23
- 20-Feb-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 10-May-24
- 12-Jul-24
- 12-Jul-24
- 0.11


- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 08-Feb-23
- 02-Aug-23
- 02-Aug-23
- 5:46
- 10
- 71
- Rights issue of equity shares of Rs. 10/- in the ratio of 5:46 @ premium of Rs. 71/-.